Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Long-term data from the TiNivo-2 trial show that tivozanib monotherapy delivers sustained survival benefits in advanced renal cell carcinoma (RCC) after prior immunotherapy — and actually outperforms the combination with nivolumab on response rates. Adding nivolumab back didn't help, confirming that ICI rechallenge offers no meaningful advantage in this setting.
Long-term follow-up data from the phase 3 TiNivo-2 trial confirm that tivozanib monotherapy delivers durable efficacy in patients with advanced renal cell carcinoma (RCC) who have already received immune checkpoint inhibitor (ICI) therapy — and it performs better than the combination with nivolumab when it comes to response rates.
The trial enrolled 343 patients with locally advanced or metastatic clear cell RCC who had progressed after one or two prior lines of therapy, including an ICI. Patients were randomized to either standard-dose tivozanib alone or reduced-dose tivozanib plus nivolumab. After a median follow-up of 27.8 months, the combination arm failed to show any PFS or OS advantage over monotherapy, reinforcing the earlier finding that ICI rechallenge offers no meaningful benefit.
Why it matters: Post-ICI treatment options for advanced RCC remain a significant unmet need. These results reinforce tivozanib monotherapy as a reliable, well-characterized option in this challenging setting, with no added benefit — and added complexity — from combining it with nivolumab.